Summary
- Profile Type
- Technology offer
- POD Reference
- TOES20250429014
- Term of Validity
- 29 April 2025 - 29 April 2026
- Company's Country
- Spain
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A research group from University of Malaga (UMA) and Miguel Hernández De Elche University (UMH) has identified an antiviral therapy based on the combined use of a base analogue and peptides that inhibit the activity of coronavirus proteins that enhance the action of the analogue. A company willing to implement and commercialize the technology through a license agreement or a technical agreement is sought.
- Full Description
-
The Andalusian research team belongs to the University of Malaga and works in the field of SARS-CoV-2 and other coronaviruses.
Some of the activities carried out by the research group are focused on the field of microbiology and genetics. The present invention provides a therapy for the treatment of serious diseases caused by infection with SARS-CoV-2 and other coronaviruses that could be used as a first-line treatment in future coronavirus pandemics.
Backgroud: In 2002-2003, SARS affected 8,098 people worldwide and caused 774 deaths, including healthcare workers. Ten years after that, the Middle East respiratory syndrome coronavirus (MERS or nCoV-2012) emerged in the Middle East and continues to appear with sporadic cases and localized outbreaks. The outbreak of pneumonia (disease named as COVID-19 by WHO on February 11, 2020) caused by coronavirus 2019-nCoV or SARS-CoV-2 in Wuhan, Hubei province of China, at the end of 2019 is a major challenge for public health and clinical treatment.
All of these coronaviruses have had significant human morbidity and mortality, especially SARS-CoV-2 with more than 692 million cases worldwide, of which 6.9 million people have died (1% of those affected). These RNA viruses are emerging pathogens with outbreak potential due to the inherent propensity of their RNA genomes for rapid mutation and recombination.
The proposed invention arises as a solution to this problem of developing an antiviral drug for the treatment of COVID-19. As a result, the surprising potential of the drug developed for use as an antiviral against viruses of the Coronaviridae family, preferably SARSCoV-2, is observed. - Advantages and Innovations
-
This invention has great advantages that are indicated below:
1) This therapy has been successfully tested against the Omicron variant of SARS-CoV-2 in cell cultures.
2) Since the targets targeted by the peptides are conserved in coronaviruses, the therapy could be used against different emerging coronaviruses.
3) The combined treatment of analogue with peptide increases the inhibition of viral infectivity and decreases the probability of the appearance of resistant variants that overcome the treatment. This confers a great advantage to this invention, since other available treatments act against a single target, with the probability of the appearance of resistance being greater.
4) This combinatorial therapy makes it possible to reduce the dose of the compounds, reducing their toxicity without losing effectiveness. - Stage of Development
- Under development
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
Partner Sought
- Expected Role of a Partner
-
Type: The team is looking for industrial partners interested in implementing and commercializing the technology worldwide. Companies that want to enter into a licensing agreement or alternatively technical agreement, in order to explore the new possibilities in the health sector are sought.
Role of partner: companies that wish to obtain patent rights as a licensee to implement and commercialize the technology at international level. - Type and Size of Partner
- Big company
- SME 50 - 249
- SME <=10
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06001018 - Virus, Virology/Antibiotics/Bacteriology
- 06001015 - Pharmaceutical Products / Drugs
- Market keywords
- 05003006 - Other therapeutic (including defibrillators)
- 05003005 - Drug delivery and other equipment
- Sector Groups Involved
- Health
- Targeted countries
- All countries